Answers are grounded in this paper and cite their sources.
Background: Atherosclerosis involves macrophage-mediated inflammation and lipid dysregulation, but genes linking sphingosine signaling to macrophage dysfunction remain incompletely characterized. Methods: GSE159677 was analyzed using Seurat and AUCell to identify sphingosine-enriched populations. Single-cell and GSE27034 bulk differentially expressed genes were integrated, followed by support vector machine–recursive feature elimination and random forest screening, with validation in GSE90074. Functional analyses assessed pathway enrichment, immune infiltration, regulatory networks, macrophage trajectories, intercellular communication, and metabolism. Network pharmacology, molecular docking, and molecular dynamics simulations prioritized potential compounds. Results: Macrophages showed the strongest sphingosine-related enrichment among six plaque cell types and greater abundance in atherosclerotic core plaques (24.71% versus 10.62%). Integration identified 22 candidate genes; SAMSN1 and STEAP4 were consistently upregulated across cohorts (p < 0.05) and were therefore prioritized as candidate genes requiring prospective validation. Enrichment analysis identified 61 shared pathways, mainly involving sphingolipid metabolism and lysosomal function. SAMSN1 correlated with resting memory and naive CD4 T cells, while STEAP4 was associated with a distinct macrophage transition state. Ophiopogonin B had the most favorable docking score for STEAP4 (−10.5 kcal/mol) and showed relatively stable binding during a 100-ns simulation. Conclusions: These findings implicate SAMSN1 and STEAP4 as candidate genes associated with sphingosine-enriched macrophages that require prospective validation, and prioritize ophiopogonin B for experimental evaluation.
No takes yet. Share an insight, caveat, or question.
Qiao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: